Dr. Paulo Falabella is the Chief Medical Officer at Rhygaze. He is a physician-scientist and seasoned drug developer with over 15 years of experience spanning gene therapy, ophthalmology, and rare diseases therapeutics.

Prior to joining Rhygaze, he led the Rare Diseases franchise at REGENXBIO, Inc., where he directed the development of multiple gene therapy programs across ophthalmology, CNS, neuromuscular, and metabolic disorders. His leadership included advancing therapies from pre-IND stages through late clinical development, with a BLA submission for clemidsogene lanparvovec (MPS II - CNS) and a Phase III program for Duchenne Muscular Dystrophy.

Earlier in his career, Dr. Falabella played a key role in the development and launch of LUXTURNA® at Spark Therapeutics — the first FDA-approved gene therapy for a genetic disease in the United States.

Dr. Falabella holds a Doctor of Medicine (M.D.) and a Ph.D. in Cell-Based Therapies and Artificial Vision, complemented by several prestigious fellowships and postdoctoral research programs in ophthalmology.